The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1251-1258.e23 , December 2009

Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three

  • Joseph A. Odhiambo, MMed

      Affiliations

    • Centre for Respiratory Diseases Research, Kenya Medical Research Institute, Nairobi, Kenya
    • ,
  • Hywel C. Williams, PhD

      Affiliations

    • Centre for Evidence Based Dermatology, University of Nottingham, Nottingham, United Kingdom
    • ,
  • Tadd O. Clayton, MSc

      Affiliations

    • Department of Paediatrics: Child and Youth Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    • Corresponding Author InformationReprint requests: Tadd O. Clayton, MSc, Department of Paediatrics: Child and Youth Health Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
    • ,
  • Colin F. Robertson, MD

      Affiliations

    • Murdoch Children's Research Institute, Melbourne, Australia
    • ,
  • M. Innes Asher, MBChB

      Affiliations

    • Department of Paediatrics: Child and Youth Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    • ,
  • ISAAC Phase Three Study Group

Received 2 July 2009 ,Revised 4 October 2009 ,Accepted 7 October 2009.

References 

  1. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis, I: derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131:383–396
  2. Williams HC, Strachan DP. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol. 1998;139:834–839
  3. Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, et al. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. J Allergy Clin Immunol. 2008;121:141–147
  4. Williams HC. Diagnostic criteria for atopic dermatitis: where do we go from here? [letter; comment]. Arch Dermatol. 1999;135:583–586
  5. Mancini AJ, Kaulback K, Chamlin SL. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol. 2008;25:1–6
  6. Arnold RJ, Donnelly A, Altieri L, Wong KS, Sung J. Assessment of outcomes and parental effect on Quality-of-Life endpoints in the management of atopic dermatitis. Manag Care Interface. 2007;20:18–23
  7. Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22:192–199
  8. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60:984–992
  9. Meltzer LJ, Moore M. Sleep disruptions in parents of children and adolescents with chronic illnesses: prevalence, causes, and consequences. J Pediatr Psychol. 2008;33:279–291
  10. Misery L, Finlay AY, Martin N, Boussetta S, Nguyen C, Myon E, et al. Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology. 2007;215:123–129
  11. Asher MI, Weiland SK ISAAC Steering Committee. The International Study of Asthma and Allergies in Childhood (ISAAC). Clin Exp Allergy. 1998;28(suppl 5):52–66
  12. Williams H, Robertson C, Stewart A, Aït-Khaled N, Anabwani G, Anderson R, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999;103:125–138
  13. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR, et al. International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups Is eczema really on the increase worldwide?. J Allergy Clin Immunol. 2008;121:947–954
  14. Ellwood P, Asher MI, Beasley R, Clayton TO, Stewart AW ISAAC Steering Committee. The International Study of Asthma and Allergies in Childhood (ISAAC): Phase Three rationale and methods. Int J Tuberc Lung Dis. 2005;9:10–16
  15. Aït-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J, et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy. 2009;64:123–148
  16. Lai C, Beasley R, Crane J, Foliaki S, Shah J, Weiland S, et al. Global variation in the prevalence and severity of asthma symptoms: Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009;64:476–483
  17. Ellwood P, Williams H, Aït-Khaled N, Björkstén B, Robertson C ISAAC Phase Three study group. Translation of questions: the International Study of Asthma and Allergies in Childhood (ISAAC) experience. Int J Tuberc Lung Dis. 2009;13:1174–1182
  18. Brenninkmeijer EE, Schram ME, Leeflang MM, Bos JD, Spuls PI. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol. 2008;158:754–765
  19. ISAAC Steering Committee. International Study of Asthma and Allergies in Childhood manual. Auckland/Münster: ISAAC Steering Committee;. 1993;
  20. Tay YK, Kong KH, Khoo L, Goh CL, Giam YC. The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. Br J Dermatol. 2002;146:101–106
  21. Martin Fernandez-Mayoralas D, Martin Caballero JM, Garcia-Marcos Alvarez L. [Prevalence of atopic dermatitis in schoolchildren from Cartagena (Spain) and relationship with sex and pollution]. An Pediatr (Barc). 2004;60:555–560
  22. Miyake Y, Yura A, Iki M. Cross-sectional study of allergic disorders in relation to familial factors in Japanese adolescents. Acta Paediatr. 2004;93:380–385
  23. Al-Sahab B, Atoui M, Musharrafieh U, Zaitoun F, Ramadan F, Tamim H. Epidemiology of eczema among Lebanese adolescents. Int J Public Health. 2008;53:260–267
  24. Hugg T, Ruotsalainen R, Jaakkola MS, Pushkarev V, Jaakkola JJ. Comparison of allergic diseases, symptoms and respiratory infections between Finnish and Russian school children. Eur J Epidemiol. 2008;23:123–133
  25. Harrop J, Chinn S, Verlato G, Olivieri M, Norback D, Wjst M, et al. Eczema, atopy and allergen exposure in adults: a population-based study. Clin Exp Allergy. 2007;37:526–535
  26. Hanifin JM, Reed ML, Eczema Prevalence, Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18:82–91
  27. Grize L, Gassner M, Wuthrich B, Bringolf-Isler B, Takken-Sahli K, Sennhauser FH, et al. Trends in prevalence of asthma, allergic rhinitis and atopic dermatitis in 5-7-year old Swiss children from 1992 to 2001. Allergy. 2006;61:556–562
  28. Lee SI, Shin MH, Lee HB, Lee JS, Son BK, Koh YY, et al. Prevalences of symptoms of asthma and other allergic diseases in Korean children: a nationwide questionnaire survey. J Korean Med Sci. 2001;16:155–164
  29. Saeki H, Iizuka H, Mori Y, Akasaka T, Takagi H, Kitajima Y, et al. Prevalence of atopic dermatitis in Japanese elementary schoolchildren. Br J Dermatol. 2005;152:110–114
  30. Girolomoni G, Abeni D, Masini C, Sera F, Ayala F, Belloni-Fortina A, et al. The epidemiology of atopic dermatitis in Italian schoolchildren. Allergy. 2003;58:420–425
  31. Schultz Larsen F, Svensson A, Diepgen TL, From E. The occurrence of atopic dermatitis in Greenland. Acta Derm Venereol. 2005;85:140–143
  32. Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J Am Acad Dermatol. 1996;34:760–764
  33. Burr ML, Limb ES, Andrae S, Barry DM, Nagel F. Childhood asthma in four countries: a comparative survey. Int J Epidemiol. 1994;23:341–347
  34. Ellwood P, Asher MI, Beasley R, Clayton TO, Stewart AW ISAAC Steering Committee and the ISAAC Phase Three Study Group. ISAAC Phase Three manual. Auckland: ISAAC International Data Centre; 2000;
  35. Chalmers DA, Todd G, Saxe N, Milne JT, Tolosana S, Ngcelwane PN, et al. Validation of the U.K. Working Party diagnostic criteria for atopic eczema in a Xhosa-speaking African population [published correction appears in Br J Dermatol 2007;156:612]. Br J Dermatol. 2007;156:111–116
  36. Schäfer T, Borowski C, Reese I, Werfel T, Gieler U. Systematic review and evidence-based consensus guideline on prevention of allergy and atopic eczema of the German Network on Allergy Prevention (ABAP). Minerva Pediatr. 2008;60:313–325
  37. ISAAC Steering Committee. ISAAC Phase Three Environmental Questionnaire. Auckland: ISAAC Steering Committee; 2009;Available at: http://isaac.auckland.ac.nz/phases/phasethree/environmentalquestionnaire/environmentalquestionnaire.htmlAccessed August 31, 2009
  38. Beasley R, Clayton T, Crane J, von Mutius E, Lai CKW, Montefort S, et al. Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6–7 years: analysis from Phase Three of the ISAAC programme. Lancet. 2008;372:1039–1048
  39. Brunekreef B, Stewart A, Anderson H, Lai C, Pearce N ISAAC Phase Three Study Group. Self reported truck traffic in street of residence and symptoms of asthma and allergic disease: a global relationship in ISAAC Phase Three. Environ Health Perspect. 2009;117:1791–1798
  40. Foliaki S, Pearce N, Björkstén B, Mallol J, Montefort S, von Mutius E, et al. Antibiotic use in infancy and symptoms of asthma, rhinoconjunctivitis and eczema in 6-7 year olds: ISAAC Phase Three. J Allergy Clin Immunol. 2009;124:982–989

 Currently the main source of funding for the ISAAC International Data Centre (IIDC) is the BUPA Foundation. Many New Zealand funding bodies have contributed support for the IIDC during the periods of fieldwork and data compilation (the Health Research Council of New Zealand, the Asthma and Respiratory Foundation of New Zealand, the Child Health Research Foundation, the Hawke's Bay Medical Research Foundation, the Waikato Medical Research Foundation, Glaxo Wellcome New Zealand, the NZ Lottery Board, and Astra Zeneca New Zealand). Glaxo Wellcome International Medical Affairs supported the regional coordination for Phase Three and the IIDC.

 Disclosure of potential conflict of interest: T. O. Clayton and M. I. Asher have received research support from the BUPA Foundation (UK). C. F. Robertson has received research support from the National Health Medical Research Council. J. A. Odhiambo and H. C. Williams have declared that they have no conflict of interest.

PII: S0091-6749(09)01535-8

doi: 10.1016/j.jaci.2009.10.009

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1251-1258.e23 , December 2009

Article Tools

* Image Usage & Resolution